Introduction / Javier Uhthoff-Orive -- Introduction / Jochen Buhling -- Resolution question Q238. Jurgen Meier -- Germany / Jochen Buhling -- Switzerland / Thierry Calame -- France / Isabelle Romet, Dora Talvard -- The Netherlands / Gertjan Kuipers -- Sweden / Jonas Westerberg -- Denmark / Nicolai Lindgreen, Nicolaj Bording -- Poland / Justyna Rasiewicz, Marta Sznajder -- United Kingdom / Tim Powell, Penny Gilbert -- United States of America / Dan Altman -- Canada / Steven Garland, Dan Davies, Lei Liu -- Australia / Sarah Matheson, Matthew Swinn -- Japan / Shoichi Okuyama -- Republic of Korea / Seong-Ki Kim, Yoon Suk Shin -- China / Amy Feng, An Chen, Simon Tianle Luo -- India / Hari Subramaniam -- Brazil / Maria Carmen de Souza Brito -- Mexico / Javier Uhthoff-Orive -- Resolution question Q238.
Summary:
Patent Protection for Second Medical Uses' explains the key jurisdictional differences and challenges in protecting and enforcing second medical use (SMU) claims. When a party proposes an SMU for a known substance or compound, special issues of patentability arise as they form an important component of the potential second-line patent protection. Jurisdictions around the world vary significantly in their treatment of such claims. This compendium of contributions from nineteen jurisdictions worldwide is the result of the need for a broader and more detailed exposition in SMU in order to allow comparison between jurisdictions.
This resource is supported by the Institute of Museum and Library Services under the provisions of the Library Services and Technology Act as administered by State Library of Iowa.